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Identity 
Other names: Cystatin-A; Cystatin-AS; STF1; STFA; 
Stefin-A 




The gene for human stefin A is located on chromosome 
3q21 and it comprises three exons of 111 bp, 102 bp 
and 226 bp in length, while the lengths of the 1st and 
2nd intron are approximately 14 Kbp and 4 Kbp, 
respectively. The conserved sequence of QVVAG is 
encoded in the 2nd exon and is not inserted by any 
introns. 
Transcription 
The transcript length of stefin A mRNA is 294 bps. 
Binding sites for AP-2 (Activating Protein 2) and Sp1 
(Selective Promoter Factor 1) regulatory elements are 
present in the promoter region and an AP-1 (Activating 
Protein 1) binding site in the 1st intron. 
Protein 
Description 
Stefin A belongs to the cystatin superfamily of cysteine 
protease inhibitors. The lack of a signal sequence and 
disulfide bonds makes stefins distinct from other 
members of the cystatin superfamily.  
Human stefin A is a single chain protein consisting of 
98 amino acid residues, with a molecular mass of 11 
kDa. Stefin A is an acidic protein with pI values 
between 4.5 - 5.0. Like other members of the cystatin 
superfamily, stefin A is reversible and  
competitive inhibitor of cysteine proteases, particularly 
cathepsin L and cathepsin S with Ki values in the 
picomolar range whereas cathepsin B inhibition is 
weaker (Ki 10-8M) . 
 
Ribbon representation of the minimised average structure of 
stefin A, illustrating the 5-stranded antiparallel b-sheet (with the 
strands marked A to E) wrapped around the central a-helix with 
the C-terminal loop running along the convex face of the sheet 
(Martin et al., 1995). 
 
Expression 
Stefin A is expressed and localized most abundantly i  
epithelial and lymphoid tissue. 
Function 
Besides protection of cytosolyc and cytoskeleton 
proteins from degradation by cysteine proteases 
accidentally released from lysosmes, several other 
functions have been suggested for stefin A. It may be 
important in the control of normal keratinocyte 
proliferation and differentiation. Also, it has been 
proposed to play a role in apoptosis, since apoptotic  
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bodies consistently stain for inhibitor, which also 
correlates with p53 activation. Stefin A should also 
protect epithelial and lymphoid tissues from cysteine 
proteases produced by pathogens invading the body. 
Increased levels of stefin A were found in 
inflammatory skin samples and psoriatic epidermis and
in inflamed gingival tissue homogenates from patients 
with periodontal inflammatory diseases. Recent genetic 
studies identified also mouse stefin A to be involved in 
a control of ovarian follicular growth and maturation. 
Homology 
Human stefin A exhibit a high degree of homology to 
other cysteine protease inhibitors of the cystatin 
superfamily which includes human stefin B and the 
homologues in other species such as cystatins alphand 
beta in rat, bovine thymus stefin C, porcine thymus 




Higher levels of stefin A in tumours have been 
determined in lung cancer, breast cancer, head and neck 
cancer and prostate cancer as well as in murine 
lymphosarcomas, hepatomas and Lewis lung 
carcinomas. These higher levels, up to a certain level, 
may counter-balance the excessive activity of cysteine 
cathepsins, associated with matrix remodelling 
resulting in the progression of the disease. On the o r 
hand, high cytosolic levels of stefin A may be relevant 
for regulation of apoptosis, when initiated via 
lysosomal cell death pathway inhibiting cathepsin B, 
which was proposed as a dominant execution protease 
in the lysosomal apoptotic pathways, induced in a 
variety of tumour cells by tumour necrosis factor alph  
(TNF-alpha). In some studies lower levels of stefins i  
tumours have been reported. For example, stefin A 
immunoreactivity was lower in lymphomas, in tumours 
of squamous epithelial cell origin as well as in prostate 
and brain tumours. Lower mRNA levels of stefin A 
have been reported in breast and esophagus tumours as 
compared to adjacent control tissues. 
Although stefins are cytosolic proteins, stefin A has 
also been detected in body fluids of cancer patients, 
such as ascitic fluid from patients with ovarian 
carcinoma and in bronhoalveolar fluid of lung cancer 
patients. Increased serum levels of stefin A in patients 
with hepatocellular carcinoma and liver cirrhosis 
correlated with tumour size and with a number of 
neoplastic lesions. Stefin A were moderately increased 
also in patients with colorectal cancer or lung cancer. 
Prognosis 
Higher levels of stefin A in tumour tissues have been 
shown to correlate with a favourable prognosis of 
cancer patients. A significant prognostic value of stefin 
A was determined in patients with lung and head and 
neck cancer. In the latter, high stefin A tumour levels 
were found as a strong factor for prediction of 
prognosis also in multivariant analysis when correlated 
with established clinical parameters. In prostate 
tumours higher cathepsin B/stefin A ratio were 
associated with more aggressive behaviour of prostate 
cancer. On the other hand, higher levels of stefin A i  
body fluids have been associated with a poor prognosis 
of cancer patients. Alterations in secretion may result in 
higher extracellular and lower intracellular levels of 
stefin A, therefore, a reverse correlation with patient' 
survival is to be expected. 
Oncogenesis 
Increased levels of cysteine protease activity, not being 
balanced by a corresponding increase of cysteine 
protease inhibitors are associated with progression of 
malignant disease and poor patient's prognosis. 
Enhanced expression of stefin A would be expected to 
diminish the tumour-associated proteolytic activity and 
indeed, there is evidence of a suppressive role of stefin 
A in various cancer types. Transfection of stefin A 
cDNA into human EC9706 esophageal squamous cell 
carcinoma cells inhibits tumour growth, angiogenesis, 
invasion, and metastasis, and this is mainly through the 
inhibiting of cathepsin B activity. 
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